Perle Bioscience, Inc. is investigating a novel combination therapy for Type 1 Diabetes Mellitus that leverages two FDA-approved agents, Cyclosporine A and Lansoprazole, to potentially achieve insulin independence in patients. The market for Type 1 Diabetes therapies is substantial, with a growing demand for innovative treatments that address the underlying autoimmune mechanisms and promote beta cell regeneration. The competitive landscape includes existing therapies that primarily focus on insulin management rather than addressing the root causes of the disease. The withdrawal of this study prior to patient enrollment raises concerns regarding the feasibility of the trial design or potential regulatory hurdles, necessitating further diligence on the company's strategic direction and alternative pathways for development.